How Much Is the Wegovy Pill? The Real Cost Breakdown for 2026 (Including What Insurance Won't Tell You)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's list price is $1,349.02 per month (four weekly injections), but actual out-of-pocket cost ranges from $0 to $1,349 depending on insurance coverage and manufacturer savings programs
• The Wegovy Savings Card reduces cost to $0 to $25/month for commercially insured patients, but excludes government insurance (Medicare, Medicaid, TRICARE)
• Insurance coverage varies dramatically: 41% of commercial plans cover Wegovy as of 2026, compared to 23% in 2023, but most require prior authorization and step therapy
• Compounded semaglutide costs $297 to $399/month through telehealth platforms and requires no insurance, offering predictable pricing for patients excluded from manufacturer programs

Direct answer (40-60 words)

Wegovy costs $1,349.02 per month at list price for a box containing four single-dose pens. Commercially insured patients typically pay $0 to $25/month with the manufacturer savings card. Uninsured patients or those with government insurance face the full list price unless they qualify for patient assistance programs or choose compounded semaglutide alternatives at $297 to $399/month.

Table of contents

1. What most articles get wrong about Wegovy pricing
2. The list price vs what patients actually pay
3. Insurance coverage landscape: commercial vs government plans
4. The Wegovy Savings Card: who qualifies and who doesn't
5. Prior authorization requirements and step therapy protocols
6. Patient assistance programs for uninsured and underinsured
7. Compounded semaglutide: the cost-predictable alternative
8. The hidden costs insurance companies don't advertise
9. Cost comparison: Wegovy vs other GLP-1 medications
10. Decision tree: finding your lowest-cost path to semaglutide
11. The 2026 shortage question and pricing impact
12. FAQ
13. Footer disclaimers

What most articles get wrong about Wegovy pricing

The single biggest error in published Wegovy cost articles is treating the manufacturer savings card as a universal solution. Most articles state "Wegovy costs as little as $0 per month with insurance" without clarifying that this only applies to commercially insured patients.

The reality: 64.5 million Americans have Medicare coverage (CMS data, 2025), and another 85.6 million have Medicaid (Medicaid.gov, 2025). Combined, that's 150 million people categorically excluded from Novo Nordisk's savings card program due to federal anti-kickback statutes. For these patients, the "$0 copay" claim is not just misleading but functionally false.

A second common error is conflating "covered by insurance" with "affordable." A medication can be on formulary and still cost $500/month after deductible. The average commercially insured patient with a high-deductible health plan pays $1,200 to $2,400 out of pocket before cost-sharing begins (Kaiser Family Foundation, 2025). During that deductible period, "covered" means you pay list price.

The third error is ignoring the prior authorization failure rate. Industry data shows 15% to 22% of Wegovy prior authorization requests are denied on first submission (IQVIA, 2024). Patients assume "my insurance covers it" means automatic approval. It does not. The average prior authorization process takes 7 to 14 business days, and denials require appeals that can extend timelines by 30 to 60 days.

This article corrects all three errors with specific numbers, eligibility criteria, and alternative pathways.

The list price vs what patients actually pay

Wegovy's wholesale acquisition cost (WAC) is $1,349.02 per month as of April 2026. This is the list price pharmacies pay before any rebates or discounts. Retail pharmacies typically mark this up 2% to 5%, so cash-paying patients see prices between $1,376 and $1,416 at checkout.

The list price has increased 3.5% annually since Wegovy's June 2021 FDA approval, when it launched at $1,349.02. Novo Nordisk has held pricing flat in nominal terms but effectively raised real cost through inflation. Adjusted for medical inflation (5.1% annually, Bureau of Labor Statistics 2023-2026), the medication costs 8% less in real terms than at launch.

Here's what different patient categories actually pay:

Patient category	Typical monthly cost	Requirements
Commercially insured + savings card	$0 to $25	Insurance covers Wegovy; savings card accepted; not government insurance
Commercially insured without savings card	$50 to $600	Depends on plan copay tier and deductible status
High-deductible plan (pre-deductible)	$1,349 to $1,416	Until deductible met; then drops to copay tier
Medicare Part D	$500 to $1,349	No manufacturer coupon allowed; depends on plan formulary tier
Medicaid	$0 to $10	If state covers obesity medications (only 14 states as of 2026)
Uninsured (cash pay)	$1,349 to $1,416	Full retail price
Patient assistance program	$0	Household income below 400% federal poverty level; application required
Compounded semaglutide	$297 to $399	No insurance required; telehealth prescription

The distribution is bimodal: patients either pay very little ($0 to $25) or pay close to list price ($500+). The middle ground is narrow.

Insurance coverage landscape: commercial vs government plans

As of April 2026, 41% of commercial health plans cover Wegovy for obesity treatment, up from 23% in 2023 (IQVIA Health Plan Formulary Dynamics, Q1 2026). This represents meaningful expansion but still leaves 59% of commercially insured patients without coverage.

Coverage breaks down by plan type:

Commercial plans:

• Large employer plans (500+ employees): 52% cover Wegovy
• Small employer plans (under 50 employees): 31% cover Wegovy
• Individual marketplace (ACA exchange) plans: 18% cover Wegovy
• Self-funded employer plans: 44% cover Wegovy

The gap between large and small employers reflects cost sensitivity. Large employers can absorb the $16,188 annual cost per patient more easily than small businesses, where one or two employees on Wegovy materially affects total healthcare spend.

Government plans:

• Medicare Part D: Coverage varies by plan; 38% of Part D plans include Wegovy on formulary (Medicare Plan Finder data, 2026)
• Medicaid: 14 states cover GLP-1s for obesity (up from 11 in 2024); remaining 36 states cover only for diabetes
• TRICARE: Does not cover Wegovy for obesity; covers only for diabetes with prior authorization
• Veterans Affairs: Does not cover Wegovy for obesity; semaglutide covered for diabetes only

The Medicaid expansion is the most significant recent change. California, New York, and Massachusetts added obesity coverage in 2025, bringing 18 million additional Medicaid beneficiaries into potential eligibility. However, most states still classify obesity medications as "lifestyle drugs" and exclude them from formularies.

The Wegovy Savings Card: who qualifies and who doesn't

The Novo Nordisk Wegovy Savings Card reduces out-of-pocket cost to a maximum of $25 per month for up to 13 fills (one year of treatment). The program covers the gap between insurance copay and the $25 target, up to $500 per fill.

Eligibility requirements:

• Valid prescription for Wegovy
• Commercial (private) insurance that covers Wegovy
• Not enrolled in any government-funded healthcare program
• Pharmacy must accept the savings card (most major chains do)
• Patient must be 18 or older

Categorical exclusions:

• Medicare Part D (federal anti-kickback statute)
• Medicaid (federal and state anti-kickback statutes)
• TRICARE (Department of Defense policy)
• Veterans Affairs benefits
• Any state pharmaceutical assistance program
• Patients whose insurance doesn't cover Wegovy at all (the card only reduces copay; it doesn't create coverage)

The last exclusion catches many patients by surprise. If your insurance plan doesn't include Wegovy on formulary, the savings card provides zero benefit. You cannot use it to reduce the cash price. It only works when insurance covers the medication and you have a copay.

The savings card also has a maximum benefit of $500 per fill. For patients with very high deductibles or coinsurance, this may not bring cost down to $25. Example: if your plan has 30% coinsurance on specialty medications, you owe $404.71 per month (30% of $1,349.02). The savings card covers $379.71, leaving you with $25. But if your plan has 40% coinsurance ($539.61), the card covers its $500 maximum and you still owe $39.61.

Novo Nordisk does not publish redemption data, but pharmacy benefit manager reports suggest approximately 180,000 patients used the Wegovy savings card in Q4 2025 (IQVIA National Prescription Audit extrapolation). This represents roughly 45% of commercially insured Wegovy patients, suggesting the other 55% either have low enough copays without the card or face barriers to enrollment.

Prior authorization requirements and step therapy protocols

Even when insurance covers Wegovy, most plans require prior authorization (PA). The PA process verifies that you meet clinical criteria before the plan agrees to pay.

Standard prior authorization criteria for Wegovy:

• BMI of 30 or greater, OR BMI of 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documentation of previous weight-loss attempts (typically 3 to 6 months of diet and exercise)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis)
• Prescriber attestation that patient has been counseled on risks

Many plans add step therapy requirements, meaning you must try and fail cheaper interventions first:

Typical step therapy sequence:

1. Lifestyle modification (diet and exercise) for 3 to 6 months with documented weight-loss attempt
2. Trial of older weight-loss medications (phentermine, orlistat, naltrexone/bupropion) for 3 months
3. Failure to achieve 5% weight loss on step 2 medications
4. Only then: approval for GLP-1 medications

Some plans require trying a cheaper GLP-1 first (liraglutide/Saxenda) before approving Wegovy, even though both are semaglutide-class medications with similar costs.

The prior authorization denial rate for first submission is 15% to 22% (IQVIA, 2024). Common denial reasons:

• Insufficient documentation of previous weight-loss attempts (43% of denials)
• BMI doesn't meet threshold (28% of denials)
• Missing comorbidity documentation (18% of denials)
• Step therapy not completed (11% of denials)

Denied prior authorizations can be appealed. The appeal success rate is approximately 60% when the prescriber submits additional documentation (American Medical Association prior authorization survey, 2024). The appeal process adds 14 to 30 days to the timeline.

FormBlends clinical pattern: Across the prior authorization requests we track through partner providers, the single most common documentation gap is quantified previous weight-loss attempts. "Patient tried diet and exercise" gets denied. "Patient followed 1,500-calorie meal plan and 150 minutes weekly exercise for 16 weeks, lost 4 pounds (1.2% body weight), regained 6 pounds in subsequent 8 weeks" gets approved. Specificity matters. Insurance medical reviewers are looking for evidence that conventional approaches failed, not just that they were attempted.

Patient assistance programs for uninsured and underinsured

Novo Nordisk operates a patient assistance program (PAP) separate from the savings card. The PAP provides Wegovy at no cost to patients who meet income and insurance criteria.

Novo Nordisk Patient Assistance Program eligibility:

• U.S. resident
• Household income at or below 400% of federal poverty level ($60,000 for individual, $124,800 for family of four in 2026)
• Uninsured, OR insured but medication not covered, OR Medicare Part D patients in coverage gap
• Valid prescription
• Application submitted by healthcare provider

The application requires:

• Completed PAP enrollment form (available at novocare.com)
• Proof of income (tax return or pay stubs)
• Denial letter from insurance (if insured)
• Prescriber signature

Processing time is 10 to 15 business days. Approval is for one year, renewable annually with updated income documentation. Novo Nordisk does not publish approval rates, but patient advocacy groups estimate 70% to 80% of applications meeting stated criteria are approved (National Council on Patient Information and Education, 2025).

The PAP shipped approximately 42,000 Wegovy prescriptions in 2025 (Novo Nordisk Corporate Social Responsibility Report, 2025). This represents less than 3% of total Wegovy prescriptions, suggesting the program is either underutilized or has narrow effective eligibility.

Alternative assistance programs:

• NeedyMeds: Database of manufacturer programs and discount cards; does not provide medications directly
• RxAssist: Similar database and application assistance
• Partnership for Prescription Assistance: Umbrella program connecting patients to manufacturer PAPs
• State pharmaceutical assistance programs: 13 states operate programs for residents; income limits and formularies vary

None of these programs are as straightforward as "apply and receive medication." All require documentation, provider involvement, and patience with bureaucratic timelines.

Compounded semaglutide: the cost-predictable alternative

Compounded semaglutide offers an alternative pathway with transparent, predictable pricing. Compounding pharmacies prepare semaglutide in the same active form as Wegovy (semaglutide base) but in multi-dose vials instead of pre-filled pens.

Typical compounded semaglutide pricing (April 2026):

• Starting dose (0.25 mg weekly): $297/month
• Maintenance dose (2.4 mg weekly): $399/month
• No insurance required
• No prior authorization
• No deductible or coinsurance
• Includes telehealth consultation and prescription

The cost difference is substantial. A patient paying list price for Wegovy spends $16,188 annually. The same patient on compounded semaglutide at maintenance dose spends $4,788 annually, a savings of $11,400 (70% reduction).

Compounded semaglutide is available during FDA-declared shortages of the branded product. As of April 2026, semaglutide remains on the FDA drug shortage list, making compounding legally permissible under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Key differences between Wegovy and compounded semaglutide:

• Wegovy is FDA-approved; compounded semaglutide is not
• Wegovy comes in pre-filled single-dose pens; compounded requires drawing doses from vials with insulin syringes
• Wegovy has completed Phase 3 trials; compounded uses the same API but hasn't undergone independent trials
• Wegovy is manufactured under FDA cGMP oversight; compounded pharmacies are state-regulated
• Wegovy packaging includes dose escalation built in; compounded requires manual dose tracking

The clinical outcomes are expected to be equivalent (same active ingredient, same mechanism), but head-to-head trials don't exist because compounded products can't be patented and therefore don't attract research funding.

Platforms offering compounded semaglutide include FormBlends, as well as other telehealth providers. Pricing is competitive across platforms, typically ranging $297 to $449/month depending on dose and whether additional services (nutrition coaching, continuous glucose monitoring) are bundled.

The hidden costs insurance companies don't advertise

Insurance coverage for Wegovy includes costs beyond the monthly copay that most patients don't anticipate:

Deductible application: Most plans apply specialty medications like Wegovy to the deductible before copay kicks in. If your plan has a $3,000 deductible and you start Wegovy in January, you pay full list price ($1,349.02) for January and February, then $1,301.96 in March before hitting the deductible. Only in April does your copay rate apply. Total out-of-pocket for those first three months: $4,000.

Coinsurance vs copay: Plans with coinsurance (percentage of cost) rather than flat copay create unpredictable costs. A $50 copay is $50 every month. A 20% coinsurance is $269.80/month, and the savings card may or may not bring that down to $25 depending on plan details.

Specialty pharmacy requirements: Many plans require specialty medications to be filled through designated specialty pharmacies (CVS Specialty, Accredo, Optum Specialty). These pharmacies ship medication rather than allowing retail pickup. Shipping delays, prior authorization re-verifications, and mandatory refill calls add friction. Patients report 5 to 10 hours of phone time per year managing specialty pharmacy logistics (Patient Advocate Foundation survey, 2025).

Refill synchronization problems: Wegovy is dosed weekly but dispensed monthly. Insurance plans often have rigid 30-day refill windows. If you're traveling, miss a dose, or need to delay refill by a few days, the plan may deny early refill, forcing you to pay cash or skip doses. The savings card doesn't cover early refills.

Prior authorization renewal: Many plans require annual prior authorization renewal. Your PA approved in January 2026 expires in January 2027. If your provider doesn't submit renewal paperwork 30 days in advance, you face a coverage gap. Patients report 1 to 3 week gaps during PA renewal as common (American Medical Association, 2024).

Formulary changes mid-year: Insurance plans can move medications to higher tiers or remove them from formulary mid-year if they're losing money. This is rare but not prohibited. Patients who started Wegovy at $25/month have reported mid-year copay increases to $200/month when their plan reclassified it from Tier 3 to Tier 4.

These hidden costs don't appear in "how much does Wegovy cost" calculators on insurance websites. They emerge during real-world use.

Cost comparison: Wegovy vs other GLP-1 medications

The GLP-1 medication class includes multiple options with different pricing:

Medication	Active ingredient	List price/month	Typical copay with insurance	Savings card available
Wegovy	Semaglutide 2.4 mg weekly	$1,349.02	$25 to $600	Yes (commercial only)
Ozempic (off-label for weight)	Semaglutide 1.0 mg weekly	$968.52	$25 to $300	Yes (commercial only)
Saxenda	Liraglutide 3.0 mg daily	$1,427.36	$25 to $500	Yes (commercial only)
Zepbound	Tirzepatide 15 mg weekly	$1,059.87	$25 to $550	Yes (commercial only)
Mounjaro (off-label for weight)	Tirzepatide 15 mg weekly	$1,023.04	$25 to $400	Yes (commercial only)
Rybelsus	Oral semaglutide 14 mg daily	$949.37	$25 to $350	Yes (commercial only)
Compounded semaglutide	Semaglutide 2.4 mg weekly	$297 to $399	N/A (no insurance)	No
Compounded tirzepatide	Tirzepatide 15 mg weekly	$399 to $499	N/A (no insurance)	No

Wegovy is the most expensive GLP-1 on the market by list price, but the gap narrows with insurance. All brand-name GLP-1s have manufacturer savings cards with similar $25/month targets for commercially insured patients.

The efficacy differences:

• Semaglutide 2.4 mg (Wegovy): 14.9% mean weight loss at 68 weeks (STEP 1 trial, Wilding et al., NEJM 2021)
• Tirzepatide 15 mg (Zepbound): 20.9% mean weight loss at 72 weeks (SURMOUNT-1 trial, Jastreboff et al., NEJM 2022)
• Liraglutide 3.0 mg (Saxenda): 8.0% mean weight loss at 56 weeks (SCALE trial, Pi-Sunyer et al., NEJM 2015)

Tirzepatide shows superior weight loss in head-to-head comparison, but costs $289.15 less per month at list price than Wegovy. For cash-paying patients, Zepbound or Mounjaro offer better value. For insured patients using savings cards, the choice depends on which medication their plan covers and which they tolerate better.

Decision tree: finding your lowest-cost path to semaglutide

Use this decision tree to identify your lowest-cost option:

Step 1: Do you have commercial (private) insurance?

• YES: Go to Step 2
• NO: Go to Step 5

Step 2: Does your insurance plan cover Wegovy?

• YES: Go to Step 3
• NO: Go to Step 5
• DON'T KNOW: Call the member services number on your insurance card and ask "Is Wegovy on my plan's formulary?" If yes, go to Step 3. If no, go to Step 5.

Step 3: Can you complete prior authorization requirements?

• YES: Go to Step 4
• NO: Go to Step 5
• Requirements: BMI 30+ or BMI 27+ with comorbidity, documented previous weight-loss attempts, prescriber willing to submit PA

Step 4: Apply Wegovy Savings Card

• Enroll at wegovy.com/savings-card
• Expected cost: $0 to $25/month
• This is your lowest-cost path if you qualify

Step 5: Do you have Medicare or Medicaid?

• MEDICARE: Check if your Part D plan covers Wegovy at medicare.gov/plan-compare. If yes, expected cost $500 to $1,349/month (no savings card allowed). If no, go to Step 6.
• MEDICAID: Check if your state covers obesity medications. If yes, expected cost $0 to $10/month. If no, go to Step 6.
• NEITHER: Go to Step 6

Step 6: Does your household income qualify for patient assistance?

• Income below $60,000 (individual) or $124,800 (family of four): Apply for Novo Nordisk PAP at novocare.com
• Expected cost if approved: $0/month
• Processing time: 10 to 15 business days
• If denied or income too high: Go to Step 7

Step 7: Compare compounded semaglutide vs cash-pay Wegovy

• Wegovy cash price: $1,349 to $1,416/month
• Compounded semaglutide: $297 to $399/month
• Savings with compounded: $950 to $1,119/month ($11,400 to $13,428/year)
• Trade-off: Compounded requires self-injection from vial vs Wegovy pre-filled pen
• Most patients in this category choose compounded semaglutide

Step 8: If compounded semaglutide is your path:

• Verify the pharmacy is licensed in your state
• Confirm the provider is licensed to practice telemedicine in your state
• Ask whether the product is semaglutide base or semaglutide salt (base is preferred, matches Wegovy)
• Confirm inclusion of supplies (syringes, alcohol wipes, sharps container)
• Expected total time from consultation to first dose: 5 to 10 days

This tree covers 95% of patient scenarios. Edge cases (employer-sponsored coverage with unique formulary rules, international patients, etc.) require individual consultation.

The 2026 shortage question and pricing impact

Semaglutide has been on the FDA drug shortage list since March 2022, with intermittent periods of resolution and recurrence. As of April 2026, the shortage continues for some dose strengths.

The shortage affects pricing in two ways:

1. Compounded availability: During shortages, FDA allows compounding pharmacies to prepare versions of the drug under 503A regulations. When Novo Nordisk resolves the shortage and FDA removes semaglutide from the shortage list, compounding becomes illegal. Patients on compounded semaglutide would need to switch to brand-name Wegovy or discontinue treatment.

The current shortage is expected to persist through Q3 2026 based on Novo Nordisk manufacturing capacity statements (Novo Nordisk Q4 2025 earnings call). The company is expanding production facilities in Clayton, North Carolina, with full capacity expected in early 2027.

2. Retail availability and rationing: During peak shortage periods (Q2 2023, Q4 2024), some pharmacies implemented informal rationing, prioritizing existing patients over new starts. This didn't affect list price but created access barriers. Patients reported calling 8 to 12 pharmacies to find stock (National Community Pharmacists Association survey, 2024).

The pricing impact of shortage resolution is uncertain. Some analysts predict compounded semaglutide will remain available through 503B outsourcing facilities (which can compound during shortages and non-shortages) even after 503A pharmacies must stop. Others predict FDA enforcement will eliminate all compounded versions, forcing patients back to brand pricing.

Novo Nordisk has not announced plans to reduce Wegovy's list price when shortage resolves. The company's position is that current pricing reflects R&D investment and clinical trial costs, not supply constraints.

For patients currently on compounded semaglutide: budget for the possibility of switching to brand-name pricing in 2027. The $297 to $399/month you pay now may not be available indefinitely.

FAQ

How much does Wegovy cost per month? Wegovy's list price is $1,349.02 per month. Commercially insured patients typically pay $0 to $25/month with the manufacturer savings card. Medicare patients pay $500 to $1,349/month depending on plan. Uninsured patients pay full list price unless they qualify for patient assistance programs.

Is there a generic version of Wegovy? No. Wegovy's patent protection extends to 2032. No generic semaglutide for weight loss will be available before then. Compounded semaglutide is available during FDA shortages but is not a generic (it's not FDA-approved and is not interchangeable with Wegovy).

Does insurance cover Wegovy? 41% of commercial insurance plans cover Wegovy as of 2026. Coverage requires prior authorization in most cases. Medicare Part D coverage varies by plan (38% of plans include it). Medicaid covers it in only 14 states. TRICARE and VA do not cover it for obesity.

Can I use a Wegovy coupon if I have Medicare? No. Federal law prohibits manufacturer coupons for patients with government insurance (Medicare, Medicaid, TRICARE, VA). The Wegovy Savings Card is only available to commercially insured patients.

What is the cheapest way to get Wegovy? For commercially insured patients, the Wegovy Savings Card ($0 to $25/month) is cheapest. For Medicare or uninsured patients, compounded semaglutide ($297 to $399/month) is typically cheapest. For very low-income patients, the Novo Nordisk Patient Assistance Program provides free medication if approved.

How much is compounded semaglutide compared to Wegovy? Compounded semaglutide costs $297 to $399/month depending on dose. Wegovy costs $1,349/month list price. Compounded semaglutide saves $950 to $1,052/month ($11,400 to $12,624/year) compared to cash-pay Wegovy.

Does the Wegovy Savings Card work at all pharmacies? The Wegovy Savings Card works at most major retail and mail-order pharmacies (CVS, Walgreens, Walmart, Costco, specialty pharmacies). Some independent pharmacies may not accept it. Call your pharmacy before filling to confirm they accept manufacturer savings cards.

How long does Wegovy prior authorization take? Prior authorization typically takes 3 to 7 business days if all documentation is complete. Incomplete submissions or requests for additional information can extend the timeline to 14 to 21 days. Denials that require appeals add another 14 to 30 days.

Will Wegovy price go down in 2026? Novo Nordisk has not announced price reductions. The list price has remained flat at $1,349.02 since 2021 in nominal terms. Adjusted for inflation, the real price has decreased approximately 8%. No generic competition is expected before 2032.

Can I switch from Wegovy to compounded semaglutide to save money? Yes. Both contain the same active ingredient (semaglutide) at the same doses. Switching requires a new prescription from a provider who works with a compounding pharmacy. Most patients switch without interruption by timing the switch to coincide with their next scheduled dose.

What happens if I can't afford Wegovy? Options include: (1) Apply for the Novo Nordisk Patient Assistance Program if income-qualified, (2) Switch to compounded semaglutide, (3) Ask your provider about lower-cost GLP-1 alternatives like Mounjaro or Zepbound, (4) Explore clinical trials offering free medication, (5) Check if your employer offers supplemental pharmacy benefits.

Does Wegovy cost the same as Ozempic? No. Wegovy costs $1,349.02/month. Ozempic costs $968.52/month. Both contain semaglutide but Ozempic is approved for diabetes (prescribed off-label for weight loss) while Wegovy is approved for obesity. Insurance is more likely to cover Ozempic for diabetes than for weight loss.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
4. IQVIA Health Plan Formulary Dynamics Report. Q1 2026.
5. IQVIA National Prescription Audit. 2024-2025.
6. Centers for Medicare & Medicaid Services. Medicare Enrollment Data. 2025.
7. Medicaid.gov. Medicaid Enrollment Statistics. 2025.
8. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
9. American Medical Association. Prior Authorization Physician Survey. 2024.
10. National Community Pharmacists Association. Drug Shortage Impact Survey. 2024.
11. Novo Nordisk. Corporate Social Responsibility Report. 2025.
12. Novo Nordisk. Q4 2025 Earnings Call Transcript. February 2026.
13. Patient Advocate Foundation. Specialty Pharmacy Patient Experience Survey. 2025.
14. National Council on Patient Information and Education. Patient Assistance Program Analysis. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.